Operating Company Healthcare

Fortis Life Sciences

Boston, Massachusetts, United States

Fortis Life Sciences partners with diagnostics and life sciences companies to design, validate, and manufacture solutions. It provides end-to-end capabilities (including R&D and GMP/ISO 13485-compliant manufacturing) and a portfolio of in-house manufactured and validated reagents and solutions sold under brands including Abcore, Arista Biologicals, Bethyl, Empirical Bioscience, IPOC, nanoComposix, and Vector Biolabs.

Focus Areas
Diagnostics reagent development, In-vitro diagnostics manufacturing, Lyophilized reagents & assay components
Website
fortislife.com

Tracked deals

3

3 tracked deals across 2021-2023.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Addon

3 addon

Fortis Life Sciences Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Fortis Life Sciences. 1 2021 1 2022 1 2023

Supporting Data

Recent Transactions

  • Fortis Life Sciences Acquires International Point of Care
    July 12, 2023
    Buyer
    Fortis Life Sciences, LLC
    Target
    International Point of Care, Inc.
    Industry
    Medical Devices
    Location
    Ontario, Canada
    Type
    Addon

    Fortis Life Sciences, LLC has acquired Toronto-based International Point of Care, Inc. (IPOC). The acquisition adds IPOC’s 36,000 sq. ft. GMP and ISO 13485:2016 manufacturing facility and capabilities (lyophilized reagents, membranes, recombinant proteins, and controls) to Fortis’ diagnostics manufacturing platform, enabling end-to-end customizable solutions for immunodiagnostic and molecular diagnostic customers.

  • Fortis Life Sciences Acquires Abcore
    March 2, 2022
    Buyer
    Fortis Life Sciences
    Target
    Abcore
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Addon

    Fortis Life Sciences has acquired Abcore, an antibody discovery platform specializing in nanobody technologies, to expand Fortis’ antibody product and service capabilities. The acquisition brings Abcore’s end-to-end discovery and custom antibody production capabilities into the Fortis platform to accelerate commercial and operational scale-up for biopharma and diagnostic customers.

  • Fortis Life Sciences Acquires nanoComposix
    July 23, 2021
    Buyer
    Fortis Life Sciences
    Target
    nanoComposix
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Addon

    Fortis Life Sciences completed its acquisition of nanoComposix, a San Diego–based nanomaterials company focused on assay development, diagnostics and drug-delivery applications. The deal (closed June 2021) brings nanoComposix into the Fortis Life Sciences platform to expand its life-science reagents and contract-manufacturing capabilities and create synergies across the portfolio.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 2 tracked deals by Fortis Life Sciences. Medical Devices Buyers & Acquisitions 1 tracked deal by Fortis Life Sciences. Acquisitions in California 2 tracked deals by Fortis Life Sciences.

Related articles

Selling a company? Get in front of buyers like Fortis Life Sciences

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →